Spero Therapeutics Stock More Than Doubles On GSK Pact For Its Lead Antibiotic

GSK Plc (NASDAQ: GSK) has entered into an exclusive license agreement for Spero Therapeutics Inc's (NASDAQ: SPRO) late-stage antibiotic asset, tebipenem HBr. Tebipenem HBr is being developed as the first oral carbapenem antibiotic for complicated urinary tract infections (cUTI). Spero expects to start a new phase 3 trial in 2023, following encouraging FDA regulatory feedback on the proposed trial design. Spero received an FDA Complete Response Letter in June 2022, citing data from Spero's initia
Click Here To Get Funded!